Trial Profile

Special Drug Use Investigation of Xarelto [SPAF]

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary)
Indications Embolism; Ischaemic stroke; Myocardial infarction
Focus Adverse reactions; Therapeutic Use
Acronyms XAPASS
Sponsors Bayer

Most Recent Events

01 Sep 2020 Results (n=11,308 ) of sub-analysis of XAPASS assess long-term safety and effectiveness of reduced-dose rivaroxaban in high-risk NVAF patients for bleeding and thromboembolism presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
03 Feb 2020 Status changed from active, no longer recruiting to completed.
08 Feb 2019 One year follow-up results (n=9578) were presented at the International Stroke Conference 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com